World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
70
Citations
23167
World Ranking
6890
National Ranking
3177

Overview

Wells A. Messersmith is affiliated with the University of Colorado Boulder in the United States. Their primary research area lies within Medicine, with a strong focus on Oncology, encompassing 145 publications in this subfield. Additional subfields include Pulmonary and Respiratory Medicine, Cancer Research, Immunology, and Surgery. Their work spans various cancer-related topics and clinical research.

The scientist's research concentrates on several key topics, including:

  • Pancreatic and Hepatic Oncology Research
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Genomics and Diagnostics
  • Genetic factors in colorectal cancer
  • Neuroendocrine Tumor Research Advances
  • Gastric Cancer Management and Outcomes

Messersmith has contributed to multiple publications in prestigious journals. Frequent publication venues for their research include:

  • Journal of Clinical Oncology
  • Journal of the National Comprehensive Cancer Network
  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Clinical Cancer Research

Several recent papers authored or co-authored by Messersmith illustrate a focus on gastrointestinal cancers and emerging cancer therapies. These include:

  • "Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology," 2021, Journal of the National Comprehensive Cancer Network
  • "Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology," 2022, Journal of the National Comprehensive Cancer Network
  • "NCCN Guidelines Insights: Rectal Cancer, Version 6.2020," 2020, Journal of the National Comprehensive Cancer Network
  • "Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial," 2021, Annals of Oncology
  • "Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas," 2021, Clinical Cancer Research

Frequent collaborators in their research include Christopher H. Lieu, Alexis D. Leal, Todd M. Pitts, Robert W. Lentz, and S. Lindsey Davis. These co-authors have contributed significantly to multi-author publications alongside Messersmith, reflecting collaborations in clinical oncology and cancer research.

Best Publications

  • Patient-derived tumour xenografts as models for oncology drug development

    John J. Tentler;Aik Choon Tan;Colin D. Weekes;Antonio Jimeno

  • Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Al B. Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Mustafa A. Arain

  • Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

    Al B. Benson;Alan P. Venook;Lynette Cederquist;Emily Chan

  • NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • Rectal cancer, version 2.2018 clinical practice guidelines in Oncology

    Al B Benson;Alan P. Venook;Mahmoud M. Al-Hawary;Lynette Cederquist

  • Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.

    Gerald S Falchook;Karl D Lewis;Jeffrey R Infante;Michael S Gordon

  • Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

    Jeffrey R. Infante;Leslie A. Fecher;Gerald S. Falchook;Sujatha Nallapareddy

  • Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-Mutant colorectal cancer

    Ryan B. Corcoran;Chloe E. Atreya;Gerald S. Falchook;Eunice L. Kwak

  • An In vivo Platform for Translational Drug Development in Pancreatic Cancer

    Belen Rubio-Viqueira;Antonio Jimeno;George Cusatis;Xianfeng Zhang

  • Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.

    Aditya Bardia;Ingrid A. Mayer;Jennifer R. Diamond;Rebecca L. Moroose

  • Rectal cancer, version 6.2020: Featured updates to the NCCN guidelines

    Al B. Benson;Al B. Benson;Alan P. Venook;Alan P. Venook;Mahmoud M. Al-Hawary;Mahmoud M. Al-Hawary;Mustafa A. Arain;Mustafa A. Arain

  • Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

    Anthony W. Tolcher;Wells A. Messersmith;Stanislaw M. Mikulski;Kyriakos P. Papadopoulos

  • KRAS Mutations and Sensitivity to Epidermal Growth Factor Receptor Inhibitors in Colorectal Cancer: Practical Application of Patient Selection

    Antonio Jimeno;Wells A. Messersmith;Fred R. Hirsch;Wilbur A. Franklin

  • Rectal cancer, version 2.2015: Featured updates to the NCCN guidelines

    Al B. Benson;Alan P. Venook;Tanios Bekaii-Saab;Emily Chan

  • The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.

    Ihab R. Kamel;David A. Bluemke;John Eng;Eleni Liapi

  • Colon Cancer, Version 3.2014

    Al B. Benson;Alan P. Venook;Tanios Bekaii-Saab;Emily Chan

  • A phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014

    Wells A. Messersmith;Geoffrey I. Shapiro;James M. Cleary;Antonio Jimeno

  • A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors

    David S. Hong;Daniel W. Bowles;Gerald S. Falchook;Wells A. Messersmith

  • Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.

    A. Bardia;W.A. Messersmith;E.A. Kio;J.D. Berlin

  • Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokinetics

    Allyson J. Ocean;Alexander N. Starodub;Aditya Bardia;Linda T. Vahdat

Frequent Co-Authors

Antonio Jimeno
Antonio Jimeno University of Colorado Boulder
Manuel Hidalgo
Manuel Hidalgo Cornell University
Aik Choon Tan
Aik Choon Tan University of Utah
Jordan Berlin
Jordan Berlin Vanderbilt University Medical Center
David M. Goldenberg
David M. Goldenberg Immunomedics (United States)
Robert M. Sharkey
Robert M. Sharkey University of Fukui
Sharyn D. Baker
Sharyn D. Baker The Ohio State University
Ross C. Donehower
Ross C. Donehower Johns Hopkins University
Martin D. McCarter
Martin D. McCarter University of Colorado Anschutz Medical Campus
Aditya Bardia
Aditya Bardia Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees and career pathways is a great way to shape your future in Biology and Biochemistry. Many students consider top dietetics programs in the us as a next step, blending biology knowledge with nutrition science to pursue licensure as a registered dietitian.

If you’re interested in hands-on healthcare positions, look into online medical assistant programs with financial aid. These programs offer flexible pathways into medical support roles and often include financial support options to help make your education affordable.

For those already working as medical assistants and seeking career growth, an ma to lpn bridge program can help you transition into a Licensed Practical Nurse role, expanding your scope of practice and earning potential.

Finally, students looking for a fast-track bachelor's degree in biology should consider online biology programs with accelerated options, which are ideal for motivated learners eager to advance quickly.

Best Scientists Citing Wells A. Messersmith

Trending Scientists